Tower Cancer Research stakes its work on promise.
For breast cancer patients, early detection is crucial. Earlier diagnosis tracks with more immediate treatment, which is key to better outcomes. Our role at Tower is to grow the promising research and development to ensure better outcomes for more women.
So it is with great satisfaction that I am pleased to report the granting of a US patent to CyDuct Diagnostics, a leader in women’s health and precision medicine. CyDuct’s non-invasive testing is a breakthrough women deserve.
For the past few years, the gold standard in breast cancer detection technology has involved “liquid biopsy” – a blood test that can detect cancer cells. This comprehensive genomic profiling approach was groundbreaking at the time, and remains critical to many thousands of patients worldwide.
Now, CyDuct’s testing promises enhanced efficacy with a less invasive procedure.
By gently harvesting fluid from the breast through the nipple, with just a drop, CyDuct is able to conduct molecular analysis of breast fluid to provide doctors with an objective assessment of a woman’s breast health and detect early warning signs of ductal cellular changes.
Personalized precision diagnostics at the ductal site will be new to market – and patients – later this year. This breakthrough is based on years of work and creative intelligence. X years ago, at the international Breast Symposium in Los Angeles, CyDuct was awarded a development grant from the Dr. Susan Love Foundation. Susan herself voted to support this work which extended her vision. As steward of the Dr. Susan Love Fund, Tower continued to fund this effort through the patent phase.
Identifying and advancing the most innovative researchers asking the best questions and testing novel hypotheses is the nature of discovery, and that is our singular focus.
As CyDuct’s Halo diagnostics begins its work in the world, we remain committed to elevating the next breakthroughs.